Introduction
Myelodysplastic syndrome (MDS) represents a heterogeneous group of hematopoietic stem cell disorder characterized by peripheral cytopenia(s), bone marrow dysplasia, and susceptibility to acute leukemia (AL). 1 Although the precise pathogenesis of MDS remains to be clarified, cytogenetic abnormalities seem to be involved in disease mechanism and are considered as an important factor in predicting clinical outcome. [2] [3] [4] Disease natures of MDS are extremely variable and racial differences were previously reported between Asian and Western countries. 5 However, no systematic study has been undertaken in large series of Chinese patients. In this multicentric study, clinical, and cytogenetic data were analyzed in 508 cases with primary MDS in China in order to compare the phenotype, cytogenetic profile as well as the possible underlying causes with those of Western countries. The prognostic significance of cytogenetic abnormalities was also evaluated, and the effect of cytogenetic abnormalities on MDS progression addressed.
Materials and methods

Patients
From January 1990 to March 2003, 508 consecutive patients with primary MDS were included in this retrospective study. Thorough morphological review and immunohistochemistry studies were performed and the diagnosis was established according to the FAB criteria. 6 Patients with a history of prior chemoradiotherapy and those with secondary MDS were excluded from this analysis. All patients provided informed consent and the University and Institutional Review Boards approved all research studies.
Cytogenetics
Cytogenetic analyses from bone marrow cells were available from 367 patients. Chromosomes were R-and G-banded on unstimulated bone marrow cells after 24-h culture. Karyotypes were classified according to International System for Human Cytogenetic Nomenclature. 7 Inclusion in the study required the analysis of X20 metaphase cells per patient. For multiplex fluorescence in situ hybridization (M-FISH) analysis, the SpectraVysion Assay (Vysis, USA) was performed according to the manufacturers' recommendations. The whole chromosome paint (WCP DNA probe) panel provided by SpectraVysiont is directly labeled with the five different fluorescences in a combinatorial labeling format to provide 24 distinct colors to identify the 24 chromosomes when analyzed with the Cytovision System (Applied Imaging, UK).
For clinical/cytogenetic categorization, patients were classified according to scoring systems related to karyotype, including international prognostic scoring system (IPSS) 4 , Lille system 2 (calculated by platelet counts, bone marrow blasts and karyotype) and Tokyo system 3 (calculated by neutrophil counts, hemoglobin level, platelet counts, bone marrow blasts and karyotype).
Statistics
The percentages of cytogenetic abnormalities according to FAB subtypes were compared using w 2 analyses and the Fisher exact test. Overall survival (OS) was measured from the date of diagnosis to either death from any cause or the date of last follow-up through April 2003. The survival and leukemia transformation rates were estimated using Kaplan-Meier method and compared by log-rank test. Multivariate analysis was performed using a Cox proportional hazards regression model. P-values less than 0.05 were considered statistically significant. All statistical analyses were evaluated using SAS 8.2 software (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics and outcome
There were 292 (57.5%) males and 216 (42.5%) females and the median age was 49 years (range: 13-92 years). Of note, patients from the rural regions (42 years) were relatively younger than those from the cities (53 years). The proportions of patients with FAB subtypes were as follows: 223 (43.9%) cases of refractory anemia (RA), 14 (2.8%) cases of RA with ringed sideroblasts (RARS), 137 (27.0%) cases of RA with excess blasts (RAEB), 107 (21.1%) cases of RAEB in transformation (RAEB-T), and 27 (5.2%) cases of chronic myelomonocytic leukemia (CMML). The age distribution of the patients according to FAB subtype and region was illustrated in Figure 1 . In this series, RARS occurred only in patients X50 years and CMML mostly in patients X30 years, while the other three subtypes were found in all age stages.
Data of hepatitis B virus infection were available for 200 patients and 42 of them were HBsAg positive. In precedence, 78 patients had exposure to benzene or its derivatives, 33 patients had cytomegalovirus infection, and 22 patients had tuberculosis infection. However, probably due to limited number of the cases, no obvious variation of clinical features was observed between the groups with or without the above contact. Analysis of lymphocyte surface markers was performed in 110 patients and 86 (78.2%) cases showed decreased percentage of CD3 þ T lymphocytes, with CD3 þ CD4 þ cells more severely affected than CD3 þ CD8 þ cells. The serum immunoglobin level of those patients was normal.
Among the 470 patients with follow-up data, 54 (11.5%) patients received supportive care only, whereas the majority of the patients (416, 88.5%) received additional treatments: 261 (55.5%) received all-trans retinoic acid and cholecalciferols, 139 (29.6%) received low-dose chemotherapy with cytosine arabinoside (Ara-C 25 mg/m 2 /day) and aclamycin (5 mg/m 2 /day) in 2week course, 46 (9.8%) received low-dose chemotherapy with hydroxyurea or etoposide (25 mg/m 2 /day) in 2-week course, 58 (12.3%) received standard chemotherapy (anthracycline and Ara-C combination), and eight (1.7%) received allogeneic peripheral stem cell transplantation from an HLA identical sibling. The therapeutic selection was not randomized, but was based on age, general condition, and severity of cytopenias. No significant superiority was shown among the groups with different treatments. The median OS of the patients was 34 months (range 1-161 months) with 2 and 5 year of OS 50.0 and 15.0%, respectively. A total of 173 cases (36.8%) developed AL, within 1-161 months after diagnosis (median 50 months).
Clinical data with respect to FAB subtypes, median age at diagnosis, male/female ratio, hematological features, AL transformation, and survival time were listed in Table 1 .
Incidence of cytogenetic abnormalities in MDS
Of the 367 patients with available cytogenetic data, 231 cases (62.9%) demonstrated undetectable karyotypic abnormalities, while 136 cases (37.1%) showed abnormal karyotype, including numerical changes (56 cases, 15.3%) and structural changes (80 cases, 21.8%). Higher incidence of cytogenetic abnormality was found in RAEB-T (43/86, 50.0%) and RAEB (44/106, 41.5%) patients than that in RA patients (38/143, 26.6%). RAEB and RAEB-T groups contained more cases of nonhypodipoid, single balanced translocation, and complex aberrations ( Table 2 ).
Distributions of cytogenetic abnormalities in MDS
As the main cytogenetic abnormalities in MDS, trisomy 8 ( þ 8) was observed in 35/136 (25.7%) cases, monosomy or deletion of the long arm of chromosome 20 (À20/20qÀ) in 20/136 (14.7%) cases, monosomy or loss of a long arm of chromosome 5 (À5/5qÀ) in 17/136 (12.5%) cases, monosomy 21 (À21) in 8/ 136 (5.9%) cases, and monosomy or loss of a long arm of chromosome 7 (À7/7qÀ) in 6/136 (4.4%) cases. However, most of them had additional chromosome changes. As a single Age distribution in MDS according to FAB subtype and regions. All the patients were grouped by decades from p20 to 480 year old. According to FAB subtype (a), RARS was only found in patients 450 years and CMML mostly in patients 430 years. According to regions (b), the patients p50 years were more often from the rural regions, while the patients 450 years were more often from the cities.
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B Chen et al aberration, the number and the percentage of these abnormalities were only 16 (11.8%), 11 (8.1%), 2 (1.5%), 1 (0.7%), and 1 (0.7%), respectively. According to the MDS subtypes, cytogenetic abnormalities were present in 80 chromosome segments in RA, nine in RARS, 144 in RAEB, and 142 in RAEB-T. Duplications were mostly seen in RA (37/80, 46.3%), while translocations were predominantly found in RAEB (40/144, 27.8%) and RAEB-T (47/142, 33.1%). As shown in Figure 2 , in RA, the most frequent aberrations were dup(1)(q21q41), þ 8, and À20/ 20qÀ[del(20)(q11)]. In RAEB, À5/5qÀ, þ 8, and À20/ 20qÀ[(del(20)(q11)] were major abnormalities observed. Cytogenetic abnormalities, especially chromosome deletions, were revealed on almost every chromosome. Simple and complex translocations, marker chromosome and other kind of structural abnormalities were also detected. In RAEB-T, dup(3)(q21q29), À5/5qÀ, À7/7qÀ[del(7)(q22q35)], þ 8, À18, marker chromosome, especially the simple and complex translocations constituted the special pattern of abnormalities.
Chromosome translocations in MDS
The chromosome translocations and the genes involved were listed in Table 3 . Simple translocation generally occurred in younger patients. t(8;21) was found in three cases, t(7;11), t(3;5), and t(1;7) were found each in two cases. 3, 5, 8, 9) . À5/5qÀ were found in six cases as additional abnormalities. In case 8, the most complex translocations involved 14 chromosomes with seven different translocations. Figure 3 showed the complex translocations confirmed by M-FISH analysis.
Impact of cytogenetics on leukemia progression and survival time
Among 329 patients with both available karyotype and followup data, survival analysis showed that IPSS had more significant P-value in predicting disease outcome (Po0.0001) than Lille and Tokyo system (P ¼ 0.0096 and 0.0080, respectively). As for the risk group distribution, compared with previous report in IPSS, fewer cases were placed in low-risk group (7.6%) and more were in intermediate and high-risk group (48.2, 26.5, and 17.7%, respectively) ( Table 4) .
Patients with abnormal karyotype exhibited a high tendency to evolve into the leukemic phase (78/122, 63.9%), as compared with those with normal karyotype (48/207, 23.2%, Po0.0001). The survival curves with respect to FAB classification, IPSS, and cytogenetic findings were presented in Figure 4 . In numerical changes, patients with hypodiploid presented with significantly early leukemia progression and short survival time (P ¼ 0.0066 and 0.0012, respectively). Although þ 8 and À20/20qÀ failed to indicate any statistically prognostic significance, survival curve of À20/20qÀ cases showed a tendency of decreased survival time (Figure 4c ). À5/5qÀ, À21, and À7/7qÀ were not listed because of the limited number of patients with those cytogenetic abnormalities as a single aberration. In structural changes, double or complex aberrations, either with or without translocation, were related to poor disease outcome (P ¼ 0.0008 to o0.0001). Simple or complex translocations also indicated poor prognosis (P ¼ 0.0003 and o0.0001, respectively). In these 25 patients, all of them with follow-up data transformed to AL and survived within 19 months (Table 3 ).
Multivariate analyses indicated that complex cytogenetic aberrations, as well as simple and complex translocations, were independently related to poor prognosis (P ¼ 0.0191, 0.0386, and 0.0158, respectively). The Cox model selected seven characteristics: karyotype, age, sex, white blood cell counts, hemoglobin concentration, platelet counts, and the percentage of bone marrow blasts.
Discussion
Despite of heterogeneous morphologic, biologic, and clinical features, MDS is generally considered as a preleukemic disorder in which the established neoplastic clone may progress to AL. 8 The disease usually occurs in the elder group in Western population. 2, 4, 9, 10 However, the median age of our patients was a decade younger, which, interestingly, is in agreement with the previous reports from Asian countries, such as Korea, 5, 11 Japan, 12 and Thailand. 13 Accordingly, low percentages of RARS and CMML were found in Asian countries (Table 4) , 3, 5, 11, 14 since these two subtypes mostly occur in older patients, as also shown in our series. Apart from the ethnic and demographic reason for this disparity, we believe that environmental factors, including chemical contamination and infectious agents may also play a role. In this study, compared with the cities, a trend of younger age was observed in rural regions, where insecticide exposure was much higher, while the distribution of FAB subtype showed no significant difference between rural regions or cities. Moreover, increased incidence of hepatitis B virus infection (42/200, 21%) was found in MDS group of patients than that of normal population previously reported in China (9.75%) (Zhuang H, Si CW et al. Zhonghua Nei Ke Za Zhi 1997; 36: 706, abstract). In addition, 78.2% of the 110 patients showed decreased percentage of CD3 þ , CD4 þ and/or CD8 þ cells, indicating that the impaired T lymphocyte surveillance might be related to occurrence of MDS. Therefore, the effect of these factors as possible MDS etiology should be addressed in larger, international comparative study and in a perspective way. MDS is often characterized by chromosome aberrations. In our study, the incidence of chromosomal abnormality increased with disease progression. Advanced stages (RAEB and RAEB-T) were associated with higher frequencies of cytogenetic abnormalities, especially double and multiple anomalies. These observations further confirmed the stepwise genetic progression model proposed in MDS pathogenesis, in which inherited or acquired genetic lesions promote the acquisition of 'secondary' genetic events mainly characterized by gains and losses of specific chromosome regions. 8 Chromosome aberrations may cause intrinsic genomic instability, which has been implicated in the pathogenesis of MDS. 15 Due to the genomic instability, certain malignant clones may acquire proliferation advantages and potentially transform to leukemia clones, while the rest were ablated through the mechanism of apoptosis. This study showed that in RAEB, deletion and loss of chromosome could occur on almost every chromosome, indicating an unstable situation of the whole genome. In RAEB-T, in spite of a lot of structural abnormalities, the occurrence of specific chromosome translocations became dominant including both balanced and complex translocations. Therefore, RAEB appears to be a stage of MDS where a genomic turbulence takes place. In RAEB-T, certain genomic abnormalities tend to be selected, particularly special translocations in favor of proliferation, survival advantage and/or differentiation arrest, which is in accordance with the clinical behavior of AL.
Different cytogenetic profiles were also present between our study and the previous ones from Western countries. In MDS of Western population, specific karyotype aberrations as a single abnormality, such as -5/5qÀ and À7/7qÀ, were more frequently reported (12.8-23.1% and 3.1-19.4%) and applied to IPSS classification (Table 4 ). 2, 4, 9, 10 In our study, patients with these aberrations as a single abnormality represented only small subsets of cases, and most of them had additional chromosome changes, and therefore included in the group of double or complex aberrations. Consequently, the percentage of complex aberrations was relatively high and more patients were positioned in intermediate and high-risk groups according to IPSS, which was different from Western countries (Table 4 ). 2, 4, 9, 10 Nevertheless, complex chromosome abnormalities still proved an independent poor prognostic factor both for survival time and leukemic transformation. These complex aberrations may also reflect genetic instability, which could facilitate stem cell clones to acquire a growth or survival By evaluating cytogenetic pattern in a relatively large group of patients, our study disclosed a series of cases with simple and complex translocations, which seem to be uncommon in MDS and not emphasized by previous reports. The t(7;11)(p15;p15) translocation resulting in the fusion gene of NUP98-HOXA9 is a chromosomal abnormality associated with acute myeloid leukemia (AML) (FAB M2 and M4) 16 and is also found in MDS. 17 Mice transplanted with bone marrow cells expressing NUP98-HOXA9 acquired a myeloproliferative disease and eventually succumbed to AML. 18 In our series, two patients presented this chromosomal abnormality. These two genes may also be involved in other translocations, such as t(2;11)(q31;p15), 19 and possibly t(7;14)(p15;q11) as well as complex translocations targeting chromosome 7p15 and 11p15, indicating that these genes may be implicated more frequently in the advanced stage of MDS. The t(8;21)(q22;q22) translocation accounted for 40% of AML having FAB M2 morphology and mice model study also proved that the resultant AML1-ETO generated dysplastic multilineage hematopoietic progenitors. 20 As recently reported in a case of RAEB-T, 21 here we encountered two cases in RAEB and one in RAEB-T. The t(3;5)(q25;q34) translocation, seen in one of our patients, rearranges NPM gene with MLF1 gene and related to MDS progression to AML. 22 Translocations involving chromosome 1 were also observed in two cases of der(1;7)(q10;p10), as previously reported in MDS, 23 and in one case with t(1;2)(q21;q37) in our series, in which we identified a new HHL (human hornerin like) gene on 1q21 and showed that its overexpression might be related to MDS/AML transformation (manuscript prepared by YY Wang, SJ Chen et al).
Clinically, these MDS patients with simple or complex chromosome translocations suffered from frequent leukemia transformation and seemed to bear very poor prognosis. Therefore, chromosome translocations, usually involved in AL pathogenesis, may contribute to the malignant progression from MDS to AL. Thus, MDS and AML appear to be different stages along with the same disease path rather than distinct disorders. Multiplex fluorescence in situ hybridization (M-FISH) analysis in nine patients with complex translocations. All the complex translocations listed in Table 3 were confirmed by M-FISH analysis. 
